{"title":"达比加群的安全性","authors":"K. O. Schneider, A. P. Kondrakhin, M. L. Maksimov","doi":"10.33920/med-03-2401-01","DOIUrl":null,"url":null,"abstract":"Thrombosis ranks first among the leading causes of death worldwide and is a fatal risk factor for patients’ health. Rapid diagnosis and appropriate treatment are necessary. There are three categories of antithrombotic agents: antiplatelet agents, anticoagulants, and fibrinolytics. Anticoagulants are first-line therapy for the prevention and treatment of venous thrombi. Dabigatran etexilate is a direct thrombin inhibitor. The effectiveness of dabigatran has been demonstrated in several clinical studies for the prevention of venous thromboembolism in patients undergoing total hip or total knee arthroplasty, for the prevention of stroke in patients with non-valvular atrial fibrillation, and in the treatment of acute venous thromboembolism. Some studies have demonstrated that the use of dabigatran leads to an increased risk of bleeding. Therefore, the purpose of this review is to examine the safety of dabigatran in patients over 18 years of age. We identified potentially relevant studies by searching the electronic databases PubMed, Web of Science, Cochrane Library, MEDLINE, and Google Scholar. Further, according to the inclusion and exclusion criteria, as well as by means of independent selection, all the authors of this article selected the sources that were suitable according to the criteria and compiled this review.","PeriodicalId":500680,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"291 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety of dabigatran\",\"authors\":\"K. O. Schneider, A. P. Kondrakhin, M. L. Maksimov\",\"doi\":\"10.33920/med-03-2401-01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Thrombosis ranks first among the leading causes of death worldwide and is a fatal risk factor for patients’ health. Rapid diagnosis and appropriate treatment are necessary. There are three categories of antithrombotic agents: antiplatelet agents, anticoagulants, and fibrinolytics. Anticoagulants are first-line therapy for the prevention and treatment of venous thrombi. Dabigatran etexilate is a direct thrombin inhibitor. The effectiveness of dabigatran has been demonstrated in several clinical studies for the prevention of venous thromboembolism in patients undergoing total hip or total knee arthroplasty, for the prevention of stroke in patients with non-valvular atrial fibrillation, and in the treatment of acute venous thromboembolism. Some studies have demonstrated that the use of dabigatran leads to an increased risk of bleeding. Therefore, the purpose of this review is to examine the safety of dabigatran in patients over 18 years of age. We identified potentially relevant studies by searching the electronic databases PubMed, Web of Science, Cochrane Library, MEDLINE, and Google Scholar. Further, according to the inclusion and exclusion criteria, as well as by means of independent selection, all the authors of this article selected the sources that were suitable according to the criteria and compiled this review.\",\"PeriodicalId\":500680,\"journal\":{\"name\":\"Glavvrač (Chief Medical Officer)\",\"volume\":\"291 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Glavvrač (Chief Medical Officer)\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.33920/med-03-2401-01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glavvrač (Chief Medical Officer)","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.33920/med-03-2401-01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
血栓形成位居全球主要死亡原因之首,是影响患者健康的致命风险因素。快速诊断和适当治疗是必要的。抗血栓药物分为三类:抗血小板药物、抗凝药物和纤溶药物。抗凝剂是预防和治疗静脉血栓的一线疗法。达比加群酯是一种直接凝血酶抑制剂。多项临床研究证实,达比加群能有效预防全髋关节或全膝关节置换术患者的静脉血栓栓塞,预防非瓣膜性心房颤动患者的中风,以及治疗急性静脉血栓栓塞。一些研究表明,使用达比加群会导致出血风险增加。因此,本综述旨在研究达比加群对 18 岁以上患者的安全性。我们通过搜索 PubMed、Web of Science、Cochrane Library、MEDLINE 和 Google Scholar 等电子数据库来确定潜在的相关研究。此外,根据纳入和排除标准,本文所有作者还通过独立筛选的方式,根据标准选择了合适的资料来源,并汇编了本综述。
Thrombosis ranks first among the leading causes of death worldwide and is a fatal risk factor for patients’ health. Rapid diagnosis and appropriate treatment are necessary. There are three categories of antithrombotic agents: antiplatelet agents, anticoagulants, and fibrinolytics. Anticoagulants are first-line therapy for the prevention and treatment of venous thrombi. Dabigatran etexilate is a direct thrombin inhibitor. The effectiveness of dabigatran has been demonstrated in several clinical studies for the prevention of venous thromboembolism in patients undergoing total hip or total knee arthroplasty, for the prevention of stroke in patients with non-valvular atrial fibrillation, and in the treatment of acute venous thromboembolism. Some studies have demonstrated that the use of dabigatran leads to an increased risk of bleeding. Therefore, the purpose of this review is to examine the safety of dabigatran in patients over 18 years of age. We identified potentially relevant studies by searching the electronic databases PubMed, Web of Science, Cochrane Library, MEDLINE, and Google Scholar. Further, according to the inclusion and exclusion criteria, as well as by means of independent selection, all the authors of this article selected the sources that were suitable according to the criteria and compiled this review.